[go: up one dir, main page]

EE200200530A - Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid - Google Patents

Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid

Info

Publication number
EE200200530A
EE200200530A EEP200200530A EEP200200530A EE200200530A EE 200200530 A EE200200530 A EE 200200530A EE P200200530 A EEP200200530 A EE P200200530A EE P200200530 A EEP200200530 A EE P200200530A EE 200200530 A EE200200530 A EE 200200530A
Authority
EE
Estonia
Prior art keywords
pharmaceutical compositions
glycogen phosphorylase
phosphorylase inhibitors
inhibitors
glycogen
Prior art date
Application number
EEP200200530A
Other languages
English (en)
Estonian (et)
Inventor
Jay Hoover Dennis
Mysore Shanker Ravi
Thomas Friesen Dwayne
Alan Lorenz Douglas
Alan Schriver Nightingale James
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200200530A publication Critical patent/EE200200530A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
EEP200200530A 2000-03-16 2001-03-16 Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid EE200200530A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18994200P 2000-03-16 2000-03-16
PCT/IB2001/000394 WO2001068055A1 (fr) 2000-03-16 2001-03-16 Compositions pharmaceutiques d'inhibiteurs du glycogene phosphorylase

Publications (1)

Publication Number Publication Date
EE200200530A true EE200200530A (et) 2004-04-15

Family

ID=22699402

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200530A EE200200530A (et) 2000-03-16 2001-03-16 Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid

Country Status (32)

Country Link
US (1) US20010053778A1 (fr)
EP (1) EP1263414A1 (fr)
JP (1) JP2003526654A (fr)
KR (1) KR20020081445A (fr)
CN (1) CN1418089A (fr)
AP (1) AP2002002621A0 (fr)
AR (1) AR027656A1 (fr)
AU (1) AU2001242669A1 (fr)
BG (1) BG107037A (fr)
BR (1) BR0109189A (fr)
CA (1) CA2403241A1 (fr)
CO (1) CO5280087A1 (fr)
CZ (1) CZ20022955A3 (fr)
EA (1) EA200200858A1 (fr)
EE (1) EE200200530A (fr)
HU (1) HUP0204583A2 (fr)
IL (1) IL151320A0 (fr)
IS (1) IS6508A (fr)
MA (1) MA26882A1 (fr)
MX (1) MXPA02009097A (fr)
NO (1) NO20024386L (fr)
OA (1) OA12232A (fr)
PA (1) PA8513601A1 (fr)
PE (1) PE20011184A1 (fr)
PL (1) PL360780A1 (fr)
SK (1) SK12622002A3 (fr)
SV (1) SV2002000343A (fr)
TN (1) TNSN01040A1 (fr)
TR (1) TR200202184T2 (fr)
WO (1) WO2001068055A1 (fr)
YU (1) YU67202A (fr)
ZA (1) ZA200207290B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20053427B (en) * 1999-12-23 2005-01-25 Pfizer Prod Inc Pharmaceutical Compositions Providing Enhanced Drug Concentrations
CO5271699A1 (es) * 2000-01-24 2003-04-30 Pfizer Prod Inc Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa
US7186745B2 (en) 2001-03-06 2007-03-06 Astrazeneca Ab Indolone derivatives having vascular damaging activity
EP1269994A3 (fr) * 2001-06-22 2003-02-12 Pfizer Products Inc. Compositions Pharmaceutiques comprenant un médicament et un polymère permettant d'améliorer la concentration du médicament
US20030170309A1 (en) * 2001-06-22 2003-09-11 Babcock Walter C. Pharmaceutical compositions containing polymer and drug assemblies
CA2450957A1 (fr) * 2001-06-22 2003-01-03 Pfizer Products Inc. Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres
AU2002302903B2 (en) * 2001-06-22 2007-05-17 Pfizer Products Inc. Pharmaceutical compositions of adsorbates of amorphous drug
WO2003063822A2 (fr) * 2002-02-01 2003-08-07 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie
CA2474958A1 (fr) 2002-02-01 2003-08-07 Pfizer Products Inc. Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen de buses de projection
ATE395044T1 (de) 2002-02-01 2008-05-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen amorpher dispersionen von wirkstoffen und lipophiler mikrophasenbildender materialien
GB0205166D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
CL2004001884A1 (es) 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
ATE540671T1 (de) 2003-08-04 2012-01-15 Bend Res Inc Pharmazeutische zusammensetzungen von adsorbaten von amorphen arzneimitteln und lipophilen mikrophasen-bildenden materialien
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
WO2005065657A2 (fr) * 2003-12-31 2005-07-21 Pfizer Products Inc. Compositions solides a base de medicaments peu solubles et de poloxameres
ES2353309T3 (es) 2004-03-08 2011-03-01 Prosidion Ltd. Hidrazidas del ácido pirrolopiridin-2-carboxílico como inhibidores de glucógeno fosforilasa.
WO2006059163A1 (fr) * 2004-12-02 2006-06-08 Prosidion Limited Traitement du diabete par des inhibiteurs de la glycogene phosphorylase
DE102005026755A1 (de) * 2005-06-09 2006-12-14 Basf Ag Herstellung von festen Lösungen schwerlöslicher Wirkstoffe durch Kurzzeitüberhitzung und schnelle Trocknung
BR112015002056A2 (pt) * 2012-08-24 2017-07-04 Dow Global Technologies Llc éter de celulose esterificado, composição, dispersão sólida, processo para produzir a dispersão sólida, forma de dosagem e invólucro de cápsula
CN105358535B (zh) 2012-09-11 2019-01-04 麦迪威森前列腺医疗有限责任公司 恩杂鲁胺制剂
CN111635353A (zh) 2013-07-19 2020-09-08 西佳技术公司 非晶形特考韦瑞制备
CN103709171B (zh) * 2014-01-20 2015-09-16 武汉大学 具有哒嗪并[3,4-b]吲哚骨架结构的衍生物及其合成方法
WO2016198983A1 (fr) 2015-06-09 2016-12-15 Bend Research Inc. Formulations pour obtenir une dissolution rapide d'un médicament à partir de dispersions séchées par pulvérisation dans des capsules
CN112442022B (zh) * 2019-09-02 2022-05-20 承德医学院 苯并嗪-4-酮类化合物、其制备方法及医药用途
US11291701B1 (en) * 2021-02-04 2022-04-05 Seed Edibles Orally disintegrating, sublingual and buccal formulations

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE205477T1 (de) * 1995-06-06 2001-09-15 Pfizer Substituierte n-(indol-2-carbonyl)-amide und derivate als glycogen phosphorylase inhibitoren
CA2224062C (fr) * 1995-06-06 2001-09-04 Pfizer Limited (indole-2-carbonyl-)-glycinamides substitues en n et leurs derives, servant d'inhibiteurs de la glycogene phosphorylase
EP0901786B1 (fr) * 1997-08-11 2007-06-13 Pfizer Products Inc. Dispersions solides pharmaceutiques à biodisponibilité accrue
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
NO20024386D0 (no) 2002-09-13
WO2001068055A1 (fr) 2001-09-20
OA12232A (en) 2006-05-10
AU2001242669A1 (en) 2001-09-24
ZA200207290B (en) 2003-09-11
EA200200858A1 (ru) 2003-02-27
CZ20022955A3 (cs) 2003-09-17
TR200202184T2 (tr) 2003-01-21
AR027656A1 (es) 2003-04-09
BR0109189A (pt) 2003-05-27
KR20020081445A (ko) 2002-10-26
PE20011184A1 (es) 2001-11-15
MA26882A1 (fr) 2004-12-20
CN1418089A (zh) 2003-05-14
JP2003526654A (ja) 2003-09-09
BG107037A (bg) 2003-04-30
IL151320A0 (en) 2003-04-10
SV2002000343A (es) 2002-07-03
TNSN01040A1 (fr) 2005-11-10
PA8513601A1 (es) 2004-08-31
YU67202A (sh) 2006-01-16
US20010053778A1 (en) 2001-12-20
IS6508A (is) 2002-08-16
EP1263414A1 (fr) 2002-12-11
NO20024386L (no) 2002-11-13
HUP0204583A2 (hu) 2003-04-28
CA2403241A1 (fr) 2001-09-20
AP2002002621A0 (en) 2002-09-30
SK12622002A3 (sk) 2004-02-03
MXPA02009097A (es) 2003-03-12
PL360780A1 (en) 2004-09-20
CO5280087A1 (es) 2003-05-30

Similar Documents

Publication Publication Date Title
EE200200530A (et) Glükogeenfosforülaasi inhibiitorite farmatseutilised kompositsioonid
AR028204A1 (es) Composiciones farmaceuticas electrohiladas
FI20105657L (fi) Farmaseuttisia koostumuksia
HU0101158D0 (en) Use of glycogen phosphorylase inhibitors
ITMI20010748A0 (it) Composizioni farmaceutiche
HUP0302412A3 (en) Betha-carboline derivatives useful as inhibitors of phosphodiesterase and pharmaceutical compositions containing the same
HUP0303146A3 (en) 3-(4-amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors and pharmaceutical compositions containing them
PT1250343E (pt) Composicoes de antibioticos de azalida
EE200300052A (et) Kolesterüülestri ülekandevalgu inhibiitorite farmatseutilised kompositsioonid
EE05020B1 (et) Glburiidi ravimkoostis
FI20011478A0 (fi) Farmaseuttinen koostumus
NO20024175L (no) Azetidinderivater, deres fremstilling og farmasöytiske preparater inneholdende forbindelsene
DK1524266T3 (da) Farmaceutisk sammensætning
DK1458377T3 (da) Farmaceutiske sammensætninger indeholdende tegaserod
EE200300589A (et) Ravimkoostised
FI20022128A0 (fi) Farmaseuttinen koostumus
NO20031095D0 (no) Farmasöytiske sammensetninger
EP1328278A4 (fr) Analgesique et compositions de glucosamine
EE200300468A (et) Pravastatiini stabiilne farmatseutiline kompositsioon
ITMI20000554A0 (it) Derivati di n-desacetiltiocolchicina e composizioni farmaceutiche cheli contengono
IS6734A (is) Tríasólafleiður og lyfjasamsetningar sem innihalda þær
EE200300465A (et) Püridoindolooni derivaatidel põhinevad farmatseutilised kompositsioonid
NO20042074L (no) Makrolider inneholdende farmasoytiske sammensetninger
EE200200689A (et) Ravimkoostised
PT1467737E (pt) Composicao farmaceutica orodispersivel de piribedil